Tekcapital Plc · LSE:TEK
Tekcapital — Investor Presentation (September 2021)
23 slides from Tekcapital's investor presentation, September 2021
Slide 1: Building Valuable Companies with University Discoveries
BUILDING VALUABLE COMPANIES WITH UNIVERSITY DISCOVERIES INVESTOR PRESENTATION September 2021 AIM:TEK, OTCQB: TEKCF © 2021 Tekcapital plc Tekcapital.com
Slide 2: Important Notice
IMPORTANT NOTICE By accepting this document, and in consideration for it being made available to such recipient, each attempt to deal in a qualifying investment or related investment (as defined in MAR) on the basis of the recipient agrees to keep strictly confidential the information contained in i
Slide 3: Transforming University Discoveries into Valuable New Products
TRANSFORMING UNIVERSITY DISCOVERIES INTO VALUABLE NEW PRODUCTS Building portfolio Providing Multi-year track companies with technology record of significant university technology transfer services growth of net assets coupled with star power for 250+ leading and returns on management universities in
Slide 4: Financial Results H1 2021
FINANCIAL RESULTS H1 2021 (US$) Objective Growth of Net Assets from commercializing university discoveries that can improve quality of life. Performance • Net assets increased 56% to $51.1m (30 Nov 2020: $32.7m) - NAV per share $0.39 (30 Nov 2020: $0.35) • Total revenue $14.5m (H1 2020: $2.9m) - Rev
Slide 5: Tekcapital's Invention Discovery Network
TEKCAPITAL’S INVENTION DISCOVERY NETWORK We have visibility to the world’s university-developed IP from 4,500 research institutions. This mitigates adverse selection and provides continuous acquisition opportunities. 5 5
Slide 6: Portfolio Companies
PORTFOLIO COMPANIES PERCENTAGE OWNERSHIP & TOTAL ADDRESSABLE MARKET (TAM) 15% 97.2%* TAM: $1.46b TAM: $1.1b CAGR: 8% CAGR: 11.5% 100%** 100% TAM: $147b TAM: $11.9b CAGR: 8.5% CAGR: 24% * Salarius Ltd owns 87.1% of MicroSalt Inc, its U.S. based subsidiary. ** Lucyd Ltd owns 80% of Innovative Eyewear
Slide 7: Premium Medical Devices at Value Prices: X-PLO2R Portable Oxygen Concentrator
Premium Medical Devices at Value Prices X-PLO2R™ Portable Oxygen Concentrator • Medical device company developing innovative oxygen therapy products. • 24 May 2021 Belluscura announcd its IPO on AIM at 45 pence per share. Tek holds 17.1m shares worth approximately $15m. • Received FDA clearance for
Slide 8: Lucyd: the clear choice for smart eyewear
Lucyd: the clear choice for smart eyewear • Goal: Upgrade your Eyewear®. Develop a successful global smart eyewear brand for prescription and sunglasses for all-day wear. • 24 August 2021- Innovative Eyewear announced Kristen Mcloughlin, Olivia Bartlett, Frank Rescigna and Louis Cstro were added to
Slide 9: Chris Clark PGA Golfer & Lucyd Brand Ambassador
Chris Clark PGA Golfer & Lucyd Brand Ambassador 9 9
Slide 10: Patented Low-sodium salt (MicroSalt)
Patented Low-sodium salt (MicroSalt®) • Salarius aims to make a dent in cardiovascular disease by providing the best, great tasting low-sodium salt that is all natural, non-GMO and Kosher • Goal: Become the leading , all natural, low-sodium salt supplier • Due to the size of the nano-particles, Micr
Slide 11: Dr. Jay Shah, Medical Advisor to MicroSalt
Dr. Jay Shah, cardiologist at Mayo Clinic & Medical Advisor to MicroSalt Play Video 11 11
Slide 12: Successful and Experienced Team
Successful and Experienced Team Salarius appointed Salarius appointed Eduardo Souchon as a Steve McCready as a director. Eduardo has 20 director. Steve served years of business, brand as Director of Product and marketing experience Development at focused on snacks (Brand Albertson’s Companies, manag
Slide 13: Software to enhance safety & efficiency of autonomous vehicles
Software to enhance safety & efficiency of autonomous vehicles & ground-based delivery devices • Goal: Provide managed software solutions for autonomous vehicle manufacturers and operators to enhance their safety. Guident is building a remote monitoring and control center (RMCC) for AV’s in Florida
Slide 14: Regenerative Shock Absorber Engineering Simulation for New Prototype Design
Regenrative Shock Absorber Engineering Simulation for New Prototype Design 14 14
Slide 15: Successful and Experienced Team
Successful and Experienced Team Guident appointed Guident appointed Johan Harald Braun as its CEO & De Nysschen as a director. Chairman. Mr. Braun has Johanis serves as COO of Volkswagen USAand served as CEO of Siemens previously served as Networks USA (NYSE: SI) Executive Vice President and Aviat N
Slide 16: Summary
SUMMARY Tekcapital commercialises university innovations for its own 1 portfolio and as a service for university clients We have built a high-value portfolio consisting of Belluscura, Lucyd, Salarius, & 2 Guident, all with exciting near-term growth prospects Tekcapital has a multi-year track record
Slide 17: Appendix
-@- TEKCAPITAL APPENDIX
Slide 18: Directors
DIRECTORS Clifford Gross, Ph.D., Chairman Cliff is passionate about commercialisation of university discoveries to improve quality of life. He founded three companies (Biomechanics Corp., UTEK & Tekcapital) which subsequently listed, where he served as CEO and Chairman and co-founded numerous privat
Slide 19: Advisors
Advisors NOMAD & BROKER AUDITORS INVESTOR RELATIONS (U.K.) SP Angel Corporate HW Fisher & Company Flagstaff Strategic and Investor Finance LLP 11-15 William Road Communications Prince Frederick House 35- LONDON NW1 3ER 1 King Street, LONDON, EC2V 8AU 39 Maddox Street +44 (0) 207 388 7000 +44 (0) 207
Slide 20: Partial Client List
O®acvevra THERAPEUTICS” CSL $ PEPSICO EAtherspoutics _ tro de tr aS de Polimeros Avanzados YEdgewel . uv Duke University Medical Center cam innovate arkansas PARTIAL CLIENT LIST y, PREDICTIVE ‘os THERAPEUTICS A UNIVERSITY OF MINNESOTA \) EMORY UNIVERSITY GW UDD Universidad del Desarrollo uT™™M. COPE
Slide 21: What Our Clients Say About Us
WHAT OUR CLIENTS SAY ABOUT US “Tekcapital helps companies of all sizes find and acquire university discoveries to create market value. We have found their offering to be well received by our listed companies that have tried their service. “ 2016 $764,444 Paul Dorfman Managing Director $953,167 NYSE
Slide 22: What Our Clients Say About Us
WHAT OUR CLIENTS SAY ABOUT US “We have had a great experience with the results of the studies we have requested." Patricia Anguita, 2016 $764,444 SubGerente de Comercializacion de Proyectos de Innovacion en Foundacion COPEC-UC $953,167 “We would recommend Invention Evaluator reports to any organizat
Slide 23: What the Press Says About Us
WHAT THE PRESS SAYS ABOUT US “In addition to a growing portfolio of university IP investments, Tekcapital helps research institutions and businesses develop disruptive technologies and expand their portfolios of intellectual capital through leveraging their suite of powerful and convenient technolog